Rim enhancement after technically successful transarterial chemoembolization in hepatocellular carcinoma: a potential mimic of incomplete embolization or reactive hyperemia?
Tomography ; 8 (2022), 2. - S. 1148-1158. - eISSN 2379-139X
Link to original publicationhttps://dx.doi.org/10.3390/tomography8020094
InstitutionsUKU. Klinik für Nuklearmedizin
UKU. Klinik für diagnostische und interventionelle Radiologie
Document versionpublished version (publisher's PDF)
Contrast enhancement at the margins/rim of embolization areas in hepatocellular-carcinoma (HCC) lesions treated with transarterial chemoembolization (TACE) might be an early prognostic indicator for HCC recurrence. The aim of this study was to evaluate the predictive value of rim perfusion for TACE recurrence as determined by perfusion CT (PCT). A total of 52 patients (65.6 ± 9.3 years) underwent PCT directly before, immediately after (within 48 h) and at follow-up (95.3 ± 12.5 days) after TACE. Arterial-liver perfusion (ALP), portal-venous perfusion (PVP) and hepatic-perfusion index (HPI) were evaluated in normal liver parenchyma, and on the embolization rim as well as the tumor bed. A total of 42 lesions were successfully treated, and PCT measurements showed no residually vascularized tumor areas. Embolization was not entirely successful in 10 patients with remaining arterialized focal nodular areas (ALP 34.7 ± 10.1 vs. 4.4 ± 5.3 mL/100 mL/min, p < 0.0001). Perfusion values at the TACE rim were lower in responders compared to normal adjacent liver parenchyma and edges of incompletely embolized tumors (ALP liver 16.3 ± 10.1 mL/100 mL/min, rim responder 8.8 ± 8.7 mL/100 mL/min, rim non-responder 23.4 ± 8.6 mL/100 mL/min, p = 0.005). At follow-up, local tumor relapse was observed in 17/42, and 15/42 showed no recurrence (ALP 39.1 ± 10.1 mL/100 mL/min vs. 10.0 ± 7.4 mL/100 mL/min, p = 0.0008); four patients had de novo disseminated disease and six patients were lost in follow-up. Rim perfusion was lower compared to adjacent recurring HCC and not different between groups. HCC lesions showed no rim perfusion after TACE, neither immediately after nor at follow-up at three months, both for mid-term responders and mid-term relapsing HCCs, indicating that rim enhancement is not a sign of reactive hyperemia and not predictive of early HCC recurrence.
Subject headings[GND]: Leberzellkrebs | Computertomografie | Embolisation
[MeSH]: Carcinoma, Hepatocellular | Liver | Four-dimensional computed tomography | Perfusion imaging | Embolization, Therapeutic
[Free subject headings]: 4D computed tomography
[DDC subject group]: DDC 610 / Medicine & health
LicenseCC BY 4.0 International
MetadataShow full item record
DOI & citation
Please use this identifier to cite or link to this item: http://dx.doi.org/10.18725/OPARU-47802